Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-26

Study Completion Date

2018-02-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch which consists of three treatment periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods) by a wash-out period. The duration of each treatment period may be extended up to a duration of 18 days if needed for operational reasons. The third treatment period was followed by a Study Completion evaluation at 1-7 days following the last dose. The treatment periods were separated by wash-out periods of 14 to 21 days duration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

NCT03063086

Asthma

COMPLETED PHASE2

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

NCT02571777

Asthma

COMPLETED PHASE3

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

NCT05776927

Asthma

NOT_YET_RECRUITING PHASE3

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

NCT03158311

Asthma

COMPLETED PHASE3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

NCT05222529

Asthma

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This study is to assess the bronchodilator effects of QVM149 dosed once daily either in the morning or in the evening for 2 weeks compared to placebo. It will provide evidence of the comparability of lung function effects of QVM149 irrespective of the administration schedule

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

This is a double-blind masking.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sequence 1

Patients will receive in a sequential order the following interventional treatments: A,B and C.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Sequence 2

Patients will receive in a sequential order the following interventional treatments: B, A and C.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Sequence 3

Patients will receive in a sequential order the following interventional treatments: C, B and A.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Sequence 4

Patients will receive in a sequential order the following interventional treatments : C, A and B.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Sequence 5

Patients will receive in a sequential order the following interventional treatments: A, C and B.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Sequence 6

Patients will receive in a sequential order the following interventional treatments: B, C and A.

Group Type EXPERIMENTAL

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Treatment C: Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Placebo (morning dose) and placebo (evening dose)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

Intervention Type DRUG

Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

Intervention Type DRUG

Treatment C: Placebo (morning dose) and placebo (evening dose)

Placebo (morning dose) and placebo (evening dose)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with a documented physician diagnosis of asthma and who additionally meet the following criteria:

* Patients receiving daily treatment with an inhaled corticosteroid at a low or medium daily dose
* On a stable regimen for at least 4 weeks prior to screening.
* Pre-bronchodilator FEV1 ≥ 60 % and \< 100% of the predicted normal value for the patient during screening.
* Patients who demonstrate an increase in FEV1 of ≥ 12 % and ≥ 200 mL after administration of 400 μg salbutamol/360 μg albuterol (or equivalent dose) at Screening. All patients must perform a reversibility test at Screening.
* At screening, and baseline (day 1 pre-dose time) of the first treatment period, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position and again in the standing position as outlined in the SOM. Sitting and standing vital signs should be within the following ranges:
* oral body temperature between 35.0-37.5 °C
* systolic blood pressure, 90-159 mmHg
* diastolic blood pressure, 50-99 mmHg
* pulse rate, 40-90 bpm
* Hypertensive patients must have been on stable antihypertensive therapy for at least 4 weeks prior to screening to be included in the trial.
* Patients must weigh at least 50 kg at screening to participate in the study, and must have a body mass index (BMI) within the range of 18 to 40 kg/m2.

Exclusion Criteria

* Contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the drugs of a similar class
* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 1 year of Screening.
* Patients who have had previous intubation for a severe asthma ttack/exacerbation.
* Patients with a history of clinically relevant bronchoconstriction upon repeated forced expiratory maneuvers.
* History of paradoxical bronchospasm in response to inhaled medicines.
* Patients who during the run-in period prior to randomization require the use of ≥12 puffs / 24 hours of rescue medication for 48 hours (over two consecutive days) or who have a decline in PEF from the reference PEFof ≥ 30% for 6 consecutive scheduled PEF readings
* Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No